Everlab secures AU$65 million to shift primary care focus from treatment to prevention.

      The Melbourne-based healthtech company Everlab, which recently closed an oversubscribed Series A funding round led by Airtree Ventures, is using the AU$65 million raised to expand into the UK and develop a system that manages a patient’s health data throughout their lifetime rather than just during individual appointments.

      Most healthcare systems are designed to respond after an issue arises, with appointments made only when symptoms appear, resulting in fragmented records and numerous specialists who seldom communicate. In contrast, Everlab, established in 2023, focuses on the idea that a more valuable system is one that identifies health problems before they become apparent to patients.

      Participating in the Series A, which was well received beyond expectations, were Airtree Ventures from Australia, Europe's Plural, and existing supporters such as Left Lane Capital in the US and b2venture in Europe. Notably, Australian Test cricket captain Pat Cummins is among the angel investors. This new funding marks a significant increase from the US$10 million seed round that the company secured less than a year ago in July 2025.

      The funding will facilitate a transition from a variety of services to a unified platform. Everlab’s application integrates diagnostics, doctors, specialists, prescriptions, and what it calls continuous AI care, allowing patients to have a comprehensive view of their health over time, rather than just fragmented snapshots.

      The company reports that it works with over 1,850 health-provider locations, more than 180 active clinicians, and over 30 wearable devices, processing around 200,000 health reports monthly.

      Marc Hermann, Everlab’s co-founder and CEO, noted, “The existing system is fragmented, passing patients between providers while hoping that information is shared.” He emphasized that Everlab was designed to provide a complete view, highlight health blind spots, and coordinate next steps in care.

      This concept echoes throughout the healthcare industry, as seen with companies like Perplexity Health and various medical wearables that feed data into clinical platforms. The emphasis is shifting from the device or appointment itself to the layer that bridges and interprets these elements.

      Everlab's metrics focus on engagement and detection. The company claims to have conducted over 40,000 consultations for 20,000 patients, including corporate clients such as Boston Consulting Group, BHP, and Bain & Company, processing more than 21 million biomarker results. Over a quarter of its members have had health issues identified that the traditional system overlooked, a key element of its preventive approach.

      Carina Namih, a partner at Plural, highlighted this distinction as the core of the investment strategy, stating, “Companies that have attempted to take control of the patient journey have generally ended up either charging by the minute for doctor consultations or reselling lab tests with narrow profit margins.” She believes that “Everlab is creating the layer above both.”

      John Henderson from Airtree was more direct about the company’s ambitions, describing Everlab as “a generational health business” already leading in Australia and poised to expand successfully on a global scale.

      The initial step in this international expansion is the United Kingdom, which Everlab identifies as its first market outside Australia and a gateway into the $10 trillion global consumer healthcare market. The funding will be directed towards enhancing its clinical and technological frameworks and accelerating its launch.

      The real challenge for the company is proving that preventive care, which is highly sought after in health systems but not often operationalized effectively, can be implemented at scale while remaining financially viable.